Hellem Tracy L
Montana State University College of Nursing, Missoula, MT 59812-7416, United States.
J Subst Abuse Treat. 2016 Dec;71:16-22. doi: 10.1016/j.jsat.2016.08.011. Epub 2016 Aug 15.
Rates of anxiety disorders among individuals who use methamphetamine are estimated to be as high as 30.2%. The presence of an anxiety disorder in methamphetamine users is associated with higher rates of relapse, non-adherence to treatment and poorer outcomes relative to methamphetamine users without an anxiety disorder. A review investigating current treatment options for methamphetamine dependence or withdrawal from methamphetamine was conducted using PubMed, CINAHL and PsycINFO. The focus of the review was trials that utilized an intervention and collected anxiety as an outcome measure. Seven studies were included in the review, and five of these studies examined a pharmacotherapy option, one studied a psychosocial intervention and one study investigated exercise as an intervention. Some of the pharmacotherapy studies and the study of exercise were associated with improvements in mood and/or a reduction in methamphetamine use. Concerns of sample size and measurement of anxiety were raised. Future well-designed research with large sample sizes is warranted to examine how to manage anxiety among methamphetamine users.
据估计,使用甲基苯丙胺的个体中焦虑症的发病率高达30.2%。与没有焦虑症的甲基苯丙胺使用者相比,甲基苯丙胺使用者中存在焦虑症与更高的复发率、不坚持治疗以及更差的治疗结果相关。使用PubMed、CINAHL和PsycINFO对当前治疗甲基苯丙胺依赖或戒除甲基苯丙胺的选择进行了综述。该综述的重点是采用干预措施并将焦虑作为结果指标进行收集的试验。该综述纳入了七项研究,其中五项研究考察了药物治疗方案,一项研究了心理社会干预措施,一项研究将运动作为干预措施进行了调查。一些药物治疗研究和运动研究与情绪改善和/或甲基苯丙胺使用量减少有关。研究中提出了对样本量和焦虑测量的担忧。有必要开展未来设计良好、样本量大的研究,以探讨如何管理甲基苯丙胺使用者的焦虑问题。